A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

Seagen

Status and phase: Completed; Phase 1

Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin

Treatments: Drug: SGN-75

Study type: Interventional

Funder types: Industry

Identifiers

NCT01015911

SGN75-001

Details and patient eligibility

About

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Enrollment: 58 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically-confirmed diagnosis of NHL or RCC
• Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy
• Confirmed CD70 expression
• Measurable disease, defined as at least 1 lesion >1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 non-resectable tumor lesion > or equal to 10 mm in diameter for patients with RCC

Exclusion criteria

• Previously received an allogeneic transplant
• History of another primary malignancy that has not been in remission for at least 3 years
• Prior anti-CD70-directed therapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

58 participants in 1 patient group

1

Experimental group

Description:

SGN-75

Treatment:

Drug: SGN-75